Patents by Inventor George Vratsanos

George Vratsanos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
    Patent number: 9012408
    Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: April 21, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
  • Method for retarding progression to definite rheumatoid arthritis in subjects with undifferentiated arthritis
    Patent number: 8435952
    Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: May 7, 2013
    Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
  • METHOD OF PREVENTING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS WITH UNDIFFERENTIATED ARTHRITIS
    Publication number: 20110142835
    Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
    Type: Application
    Filed: February 10, 2011
    Publication date: June 16, 2011
    Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
  • Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
    Patent number: 7915222
    Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: March 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
  • Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
    Publication number: 20090280119
    Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 12, 2009
    Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
  • Method of vaccinating subjects receiving immune modulating therapy
    Patent number: 7528111
    Abstract: The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases, and immune disorders associated with graft transplantation.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: May 5, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: George Vratsanos, Francisco Leon, Lee K. Tay, Kenneth M. Bahrt
  • Method of vaccinating subjects receiving immune modulating therapy
    Publication number: 20080019999
    Abstract: The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell interactions with B7-positive cells including, but not limited to, autoimmune diseases, immunoproliferative diseases, and immune disorders associated with graft transplantation.
    Type: Application
    Filed: May 8, 2007
    Publication date: January 24, 2008
    Inventors: George Vratsanos, Francisco Leon, Lee Tay, Kenneth Bahrt